Key Takeaway: Kalaris has appointed Liisa Bayko as its new Chief Financial Officer, enhancing its leadership team. With over 20 years of experience in biotechnology, Bayko's addition is expected to support the company's growth. Kalaris is currently enrolling patients in its Phase 1b/2 study of TH103 for treatment-naïve nAMD patients.
Price reaction · baseline $4.38 (2026-07-17 close) · hit pre-market · clean, no other KLRS news in the window
day 0 close
-8.7%
day 1
-7.8%
day 3 · peak
-10.5%
Market Sentiment Analysis
POSITIVE FACTORS
Appointment of Liisa Bayko as CFO strengthens leadership team.
CFO hire supports Kalaris' growth strategy.
Company is enrolling in a Phase 1b/2 study, indicating progress.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~25 mo
Minimal dilution risk
Lead asset
Multivirus-specific T cells Dose Level 1
Phase 1 · Viral Infection
Full Press Release Details
Strategic finance leader with over 20+ years of experience in the biotechnology space CFO hire bolsters Kalaris’ leadership team and supports continued growth of the company as it enrolls its Phase 1b/2 study of TH103 in treatment naïve nAMD patients BERKELEY HEIGHTS, N.J., July 20, 2026 (GLOBE
Frequently Asked Questions
Who is the new CFO of Kalaris?
Liisa Bayko has been appointed as the new Chief Financial Officer of Kalaris.
What is Liisa Bayko's experience?
Liisa Bayko has over 20 years of experience in the biotechnology sector.
What study is Kalaris currently enrolling for?
Kalaris is enrolling patients in a Phase 1b/2 study of TH103.
What condition is TH103 targeting?
TH103 is being studied for treatment-naïve nAMD patients.